RE:RE:Conventional triple negative BC drug long term side effects PFIZER, INCYTE and anti-CD47 fusion proteins - June 2022
https://www.pfizer.com/news/announcements/pfizer-morphosys-and-incyte-enter-clinical-trial-collaboration-monjuvir
In November 2021 Pfizer acquired Trillium Therapeutics for $2.26 Billion, the maker of two clinical-stage fusion proteins directed against CD47, the “do not eat me” signal that cancer cells co-opt to shield themselves from macrophage-mediated killing.
https://aacrjournals.org/cancerdiscovery/article/11/11/2666/666437/Pfizer-Acquires-Trillium-Gains-Anti-CD47